FBXL6 Protein

Activates KRAS oncogenesis

Ubiquitinates KRAS at K128 to activate both wild-type and mutant forms, driving ERK/mTOR/PRELID2/ROS axis in HCC

Xiong, Jun · Yu, Qiang · Zhang, Jie · Fang, Lei · Wu, Di · Lin, Xiao · Xie, Chuanming · Xiong, Haojun

Military Medical Research 2023

Advantages

FBXL6 is highly expressed in HCC and other human cancers (P < 0.001)

Promotes polyubiquitination of wild-type KRAS and KRASG12D at lysine 128

Dual inhibition of MEK and mTOR effectively suppresses tumor growth and metastasis in vivo